94 resultados para basophils
Resumo:
Pós-graduação em Medicina Veterinária - FMVZ
Resumo:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Resumo:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Resumo:
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Resumo:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Resumo:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Resumo:
The Cell-dyn 3500 is a multiparameter flow cytometer, which may analyze samples from several species performing several simultaneous analyses. It is able to perform white blood cells, red blood cells and platelet counts, besides differential leukocyte counts, packed cell volume and hemoglobin determination. Cell-Dyn 3500 performs total leukocyte count both optically and by impedance. The equipment may choose one or other method, based on the reliability of the results. Erythrocyte and platelet counts are determined by impedance. Leukocyte differentiation is based on an optical principle, using separation in multiangular polarized light. The objective of this study was to compare the results of complete blood count of Zebu Nellore heifers from Cell-dyn 3500, with those obtained from a semi-automated cell counter (Celm CC 510) and the manual technique. Blood samples were collected from the jugular vein in 5 mL EDTA vacuum tubes from 58 Nellore heifers, at 24 months of age. Samples were processed in parallel in the three different techniques. Results were analyzed using paired t test, Pearson's correlation and the Bland-Altmann method. There was a strong correlation for all parameters analyzed by Cell-Dyn 3500, manual method and semi-automated cell counter, except for basophils and monocytes counts. These results confirm that this analyzer is reliable for blood samples analysis of zebu cattle.
Resumo:
Pós-graduação em Cirurgia Veterinária - FCAV
Resumo:
Golden conures or ararajubas (Guaruba guarouba) are endangered parrots endemic to the Brazilian Amazon forest. Body mass, blood cell counts, and total plasma protein were determined for 70 clinically healthy golden conures captive at zoologic parks and private breeder facilities in Brazil. Hematologic results (mean +/- SD) were: Erythrocytes 3.6 +/- 0.5 x 10(6) cells/mm(3), hemoglobin 12.8 +/- 1.4 g/dl, packed cell volume 46 +/- 3.8%, mean corpuscular volume 132 +/- 20 fl, mean corpuscular hemoglobin (MCH) 36 +/- 5.7 pg, mean corpuscular hemoglobin concentration (MCHC) 28 +/- 3.5%, thrombocytes 26.3 +/- 9.3 x 10(3) cells/mm(3), leukocytes 11.9 +/- 4.5 x 10(3) cells/mm(3), heterophils 6284 +/- 2715 cells/mm(3), lymphocytes 5473 +/- 2408 cells/mm(3), monocytes 113 +/- 162 cells/mm(3), eosinophils 10 +/- 42 cells/mm(3), basophils 27 +/- 64 cells/mm(3). Body mass was 254 +/- 24.9 g and total plasma protein (TPP) was 3.54 +/- 0.58 g/dl. No statistical differences were observed between genders within age groups. Differences between juveniles (J) and adults (A) were identified for TPP < A), MCH (J > A), and MCHC (J > A). These results provide reliable reference values for the clinical interpretation of hematologic results for the species. Hematology may be an important tool for population health investigations on free-ranging golden conure populations and will also be essential to survey the health of release candidates in future reintroduction programs.
Resumo:
Die Prävalenz allergischer Erkrankungen ist in den letzten Jahrzehnten, insbesondere in den Industriestaaten, stetig angestiegen und schreitet weiterhin fort. Die einzige kausale Therapie, die eine Langzeitwirkung verspricht und der Entwicklung neuer Allergien bzw. dem Fortschreiten der Allergie vorbeugen kann, ist die spezifische Immuntherapie (SIT). Da bei der SIT mit natürlichen Allergenextrakten Nebenwirkungen auftreten können, ist es wichtig Alternativen für diese zu finden. In der vorliegenden Arbeit wurden native Allergene mit modifizierten Allergenen hinsichtlich ihrer Allergenität und Immunogenität verglichen. Hierbei konnte gezeigt werden, dass Glutaraldehyd-modifizierte Allergoide im Vergleich zu nativen Allergenextrakten und Formaldehyd-Allergoiden eine verminderte Allergenität besitzen, was sich z.B. durch den verminderten Release der Allergiemediatoren, den Leukotrienen, durch Basophile allergischer Spender zeigte. Gleichzeitig war allerdings die Fähigkeit Glutaraldehyd-Allergoid-behandelter dendritischer Zellen (DC) autologe CD4+ T-Zellen zu stimulieren stark reduziert. Verglichen mit den nativen Allergenextrakten und den Formaldehyd-Allergoiden waren die Zytokinproduktion und die T-Zellproliferation, für letztere signifikant, vermindert. Damit übereinstimmend war die Aufnahme von Fluoreszenz-markierten Glutaraldehyd-Allergoiden in unreife DC reduziert. Daraus lässt sich schießen, dass die Modifizierung mit Glutaraldehyd, jedoch nicht mit Formaldehyd, zumindest bei den hier verwendeten Allergenpräparaten, B-Zell-Epitope zerstört und somit die Allergenität herabgesetzt wurde. Allerdings war dabei gleichzeitig die Immunogenität vermindert. Das verminderte Vorkommen der B-Zell-Epitope wäre beim Einsatz der Allergoide von Vorteil, da damit eine verminderte IgE-Bindekapazität einhergeht und unerwünschte Nebenwirkungen reduziert werden können. Jedoch sollte im günstigsten Fall bei der Allergoidisierung die T-Zell-Stimulationsfähigkeit intakt bleiben, was bei den hier verwendeten Glutaraldehyd-modifizierten Allergoiden nicht der Fall war. rnMit Einzelallergenen aus Birken- und Gräserpollen konnten keine vergleichbaren T-Zellantworten erzielt werden wie mit den Gesamtallergenextrakten. Auch hier waren Proliferation und Zytokinproduktion durch CD4+ T-Zellen nach Stimulation mit Einzelallergen-gepulsten DC bei Verwendung von Glutaraldehyd-modifizierten Allergoiden vermindert. rnEine adjuvante Wirkung von Aluminiumhydroxid (Alum) in vitro konnte in dieser Arbeit nicht eindeutig gezeigt werden. Zunächst konnte beobachtet werden, dass die eingesetzten Alum-adsorbierten Allergene und Allergoide eine toxische Wirkung auf DC hatten. Die Proliferation CD4+ T-Zellen konnte durch DC, die mit Alum-adsorbierten Allergenen behandelt wurden, nicht verstärkt werden, verglichen mit DC, die mit unadsorbiertem Allergen gepulst wurden. Es konnte lediglich eine erhöhte Produktion des Th2 Zytokins IL-4 durch Alum induziert werden. Einen Adjuvanteffekt, der in Zusammenhang mit der Induktion des pro-inflammatorischen Zytokins IL-1β stehen soll, konnte mittels ELISA in den Überständen unreifer DC nicht nachgewiesen werden. Lediglich in Monozyten, die zusätzlich mit dem TLR-Ligand LPS stimuliert wurden, war IL-1β in den Überständen detektierbar. Auf mRNA-Ebene konnte man einen leichten Effekt durch Alum hinsichtlich der IL-1β Expression erkennen. Nach zusätzlicher Gabe verschiedener Alum-Präparationen zu unreifen DC, die mit Allergen oder LPS stimuliert wurden, exprimierten diese leicht verstärkt IL-1β verglichen mit DC, die kein Alum erhielten.
Resumo:
It is well appreciated that differentiation, growth, and function of basophils are regulated by a network of cytokines, and that these cells express a unique composition of surface receptors including interleukin-binding sites. In the current article, most recent discoveries around cytokine regulation of basophils are discussed and compared with previous data.
Resumo:
Aggregation of the high-affinity IgE receptor (FcεRI) with the low-affinity IgG receptor (FcγRIIb) on basophils or mast cells has been shown to inhibit allergen-induced cell degranulation. Molecules cross-linking these two receptors might therefore be of interest for the treatment of allergic disorders. Here, we demonstrate the generation of a novel bispecific fusion protein efficiently aggregating FcεRI-bound IgE with FcγRIIb on the surface of basophils to prevent pro-inflammatory mediator release.
Resumo:
IgE antibodies bind the high-affinity IgE Fc receptor (FcεRI), found primarily on mast cells and basophils, and trigger inflammatory cascades of the allergic response. Inhibitors of IgE-FcεRI binding have been identified and an anti-IgE therapeutic antibody (omalizumab) is used to treat severe allergic asthma. However, preformed IgE-FcεRI complexes that prime cells before allergen exposure dissociate extremely slowly and cannot be disrupted by strictly competitive inhibitors. IgE-Fc conformational flexibility indicated that inhibition could be mediated by allosteric or other non-classical mechanisms. Here we demonstrate that an engineered protein inhibitor, DARPin E2_79 (refs 9, 10, 11), acts through a non-classical inhibition mechanism, not only blocking IgE-FcεRI interactions, but actively stimulating the dissociation of preformed ligand-receptor complexes. The structure of the E2_79-IgE-Fc(3-4) complex predicts the presence of two non-equivalent E2_79 sites in the asymmetric IgE-FcεRI complex, with site 1 distant from the receptor and site 2 exhibiting partial steric overlap. Although the structure is indicative of an allosteric inhibition mechanism, mutational studies and quantitative kinetic modelling indicate that E2_79 acts through a facilitated dissociation mechanism at site 2 alone. These results demonstrate that high-affinity IgE-FcεRI complexes can be actively dissociated to block the allergic response and suggest that protein-protein complexes may be more generally amenable to active disruption by macromolecular inhibitors.
Resumo:
In clinical routine, adverse drug reactions (ADR) are common, and they should be included in the differential diagnosis in all patients undergoing drug treatment. Only part of those ADR are immune-mediated hypersensitivity reactions and thus true drug allergies. Far more common are non-immune-mediated ADR, e.g. due to the pharmacological properties of the drug or to the individual predisposition of the patient (enzymopathies, cytokine dysbalance, mast cell hyperreactivity). In true drug allergiesT cell- and immunoglobulin E (lgE)-mediated reactions dominate the clinical presentation. T cell-mediated ADR usually have a delayed appearance and include skin eruptions in most cases. Nevertheless, it should not be forgotten that they may involve systemic T cell activation and thus take a severe, sometimes lethal turn. Clinical danger signs are involvement of mucosal surfaces, blistering within the exanthematous skin areas and systemic symptoms, e.g. fever or malaise. Drug presentation via antigen-presenting cells to T cells can either involve the classical pathway of haptenization of endogenous proteins or be directly mediated via noncovalent binding to immune receptors (MHC molecules or T cell receptors), the so-called p-i concept. Flare-up reactions during the acute phase of T cell-mediated ADR should not be mistaken for true drug allergies, as they only occur in the setting of a highly activated T cell pool. IgE-mediated ADR are less frequent and involve mast cells and/or basophils as peripheral effector cells. Recent data suggest that certain patients with drug allergy have a preexistent sensitization although they have never been exposed to the culprit drug, probably due to cross-reactivity. Thus, allergic drug reactions on first encounter are possible. In general, the extent of cross-reactivity is higher in IgE-compared to T cell-mediated ADR. Based on a specific ethnic background and only for severe T cell-mediated ADR to certain drugs, a strong HLA association has been established recently.
Resumo:
BACKGROUND: Sialic acid-binding immunoglobulin-like lectins (Siglecs) are a family of glycan-binding inhibitory receptors, and among them, Siglec-8 is selectively expressed on human eosinophils, basophils, and mast cells. On eosinophils, Siglec-8 engagement induces apoptosis, but its function on mast cells is unknown. OBJECTIVE: We sought to study the effect of Siglec-8 engagement on human mast cell survival and mediator release responses. METHODS: Human mast cells were generated from CD34+ precursors. Apoptosis was studied by using flow cytometry. Mast cell mediator release or human lung airway smooth muscle contraction was initiated by FcepsilonRI cross-linking with or without preincubation with Siglec-8 or control antibodies, and release of mediators was analyzed along with Ca++ flux. RBL-2H3 cells transfected with normal and mutated forms of Siglec-8 were used to study how Siglec-8 engagement alters mediator release. RESULTS: Siglec-8 engagement failed to induce human mast cell apoptosis. However, preincubation with Siglec-8 mAbs significantly (P < .05) inhibited FcepsilonRI-dependent histamine and prostaglandin D(2) release, Ca++ flux, and anti-IgE-evoked contractions of human bronchial rings. In contrast, release of IL-8 was not inhibited. Siglec-8 ligation was also shown to inhibit beta-hexosaminidase release and Ca++ flux triggered through FcepsilonRI in RBL-2H3 cells transfected with full-length human Siglec-8 but not in cells transfected with Siglec-8 containing a tyrosine to phenylalanine point mutation in the membrane-proximal immunoreceptor tyrosine-based inhibitory motif domain. CONCLUSION: These data represent the first reported inhibitory effects of Siglec engagement on human mast cells.